Currently, Firdapse (amifampridine phosphate or 3,4-DAP phosphate) is in Phase III development and it will be provided at no cost until sometime following approval. Patient enrollment in the
The deal will explore the application of HemoShear’s platform in an undisclosed area of strategic interest. Initially, HemoShear will characterize biological mechanisms and the effects of drug candidates
The new products will be based on Nuvo’s patented Multiplexed Molecular Penetration Enhancer (MMPE) technology. As part of the deal, Nuvo will use its MMPE technology to formulate
The drug was not evaluated in patients with MCD who are HIV positive or HHV-8 positive because it did not bind to virally produced interleukin-6 (IL-6) in a
Both the companies’ have not disclosed the financial terms of the agreement. In July 2013, both the firms have entered into their first manufacturing agreement to collaborate in
The NDA submission was based on data from the largest Phase III program in GT1 patients conducted to date, with six Phase III studies that included over 2,300
The recently issued patent, which is the second US patent issued to ProLynx, focuses on drugs covalently coupled via the company’s patented beta-eliminative linkers to multiple sites on
Bayer is developing Ciprofloxacin DPI for NCFB patients with respiratory bacterial pathogens, including Pseudomonas aeruginosa, to reduce the frequency of acute exacerbations. These patients suffer from frequent severe
Pfizer may come back to bid for AstraZeneca as the company is looking to develop its cancer franchise, Reuters reported. According to industry analysts, Pfizer hopes that AstraZeneca’s
Under the deal, Allergan investors would receive $48.30 in cash and 0.83 of a Valeant stock for each share they own. Ackman’s Pershing Square Capital Management (Pershing Square),
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.